Study on Encorafenib, Binimetinib, and Pembrolizumab for Advanced or Metastatic Melanoma

Inclusion Criteria

• Must be 18 years or older.
• Willing to attend all scheduled visits and follow the treatment plan.
• Have advanced melanoma that cannot be removed by surgery or has spread, confirmed by medical tests.
• Have at least one measurable tumor.
• Have a performance status of 0 or 1, meaning fully active or restricted in strenuous activity but ambulatory.
• Have a specific BRAF V600E or V600K mutation in the melanoma.
• Provide a tumor sample for testing.
• Have not received prior treatment for advanced melanoma.
• Have adequate bone marrow, liver, and kidney function.
• Able to give informed consent.

Exclusion Criteria

• Have other medical or psychiatric conditions that may increase the risk of participating.
• Have mucosal or ocular melanoma.
• Have an active autoimmune disease requiring treatment in the past two years.
• Have severe drug allergies or reactions.
• Cannot swallow or absorb oral medications.
• Have significant heart disease or recent blood clots.
• Have a history of certain eye conditions.
• Have lung conditions requiring steroids.
• Have active hepatitis B, C, or HIV.
• Have an active infection needing treatment.
• Have brain metastases or other active CNS metastases.
• Have had another cancer within the past two years, except for certain skin or prostate cancers.
• Have previously stopped similar treatments due to severe side effects.
• Are pregnant or breastfeeding.
• Are involved in the study's conduct or have family members who are.